#Empagliflozin treatment effects across categories of baseline #HbA1c, body #weight and blood #pressure as an add‐on to metformin in patients with type 2 diabetes
In EMPA‐REG MET, in patients with type 2 diabetes mellitus (T2DM) on stable background metformin (≥1500 mg/day), empagliflozin versus placebo significantly improved glycated haemoglobin (HbA1c), body weight (BW), and systolic blood pressure (SBP) over 24 and ≤76 weeks. This analysis investigated empagliflozin treatment effects by baseline cardio‐metabolic factors.. ..In total, 637 patients (56.7% males; mean [SD] age 55.7 [9.9] years, HbA1c 7.9 [0.9] %, BW 81.2 … Continue reading #Empagliflozin treatment effects across categories of baseline #HbA1c, body #weight and blood #pressure as an add‐on to metformin in patients with type 2 diabetes